NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development STA Roxadustat for anaemia in chronic kidney disease

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Final appraisal determination

specific group?

(when an ACD issued)

1.	Have any additional potential equality issues been raised during the consultation, and, if so, how has the committee addressed these?
N/A	
2.	If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups?

If so, what are the barriers to, or difficulties with, access for the

No. No equality issues were identified during the appraisal.

3. If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No. No equality issues were identified during the appraisal.

people with chronic kidney disease Issue date: July 2022

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?

No. No equality issues were identified during the appraisal.

5. Have the committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?

No. No equality issues were identified during the appraisal.

Approved by Associate Director (name):Janet Robertson.......

Date: 11 July 2022

Issue date: July 2022